Strahs, Andrew L.
Université Paris-Sud · Alnylam Pharmaceuticals (United States) · Inserm · Centre Hospitalier Universitaire Henri-Mondor · Assistance Publique – Hôpitaux de Paris · Hôpitaux Universitaires Henri-Mondor · Hôpital de la Timone · Bicêtre Hospital
2 papers on CoChatORCID 0009-0006-1665-7471
Most cited papers
- Verified
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine
Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments
Cited by 3,047
- Verified
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery
Cited by 768
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free